Senescent CAFs Drive Breast Cancer Progression
2026-08-20
Ye et al. identify senescent myofibroblast cancer-associated fibroblasts as a tumor-promoting stromal population that suppresses natural killer cell cytotoxicity through extracellular matrix remodeling. Genetic or pharmacologic depletion of these senescent CAFs restored antitumor immunity in mice, while their presence in human breast lesions was associated with recurrence risk.
PARP1–FAK–COL5A1 Signaling in Ovarian Cancer
2026-08-19
The reference study identifies a cholesterol-responsive PARP1/FAK/COL5A1 signaling axis that promotes epithelial–mesenchymal transition and tumorigenesis in ovarian cancer cells adapted to persistent cholesterol exposure. Its combination of long-term conditioning, molecular perturbation, and in vitro and in vivo analyses provides a framework for studying how metabolic stress reshapes FAK-dependent cancer progression.
Necrostatin-1: RIP1 Kinase Inhibitor Guide
2026-08-19
Necrostatin-1 is a selective allosteric RIP1 kinase inhibitor used to interrogate necroptosis and tissue-injury signaling. The product dossier reports activity in TNF-α-induced necroptosis assays and mouse liver and kidney injury models, while emphasizing that assay-specific validation remains necessary.
Mannosylated LNPs for In Vivo mRNA Delivery
2026-08-18
The reference study introduces cholesterol-derived mannopolypeptides as an integrated targeting component for lipid nanoparticles, rather than relying on post-formulation antibody modification. Its CPSM-LNP and CM/CPSM-LNP systems improved dendritic-cell transfection and showed preferential lymph-node accumulation in mice, providing a preclinical framework for more targeted mRNA delivery.
Necrostatin-1 for RIP1 Kinase Assays
2026-08-18
Necrostatin-1 provides a practical pharmacological control for separating RIP1-dependent necroptosis from broader cell injury. This workflow connects necroptosis assays with bone, liver, and acute kidney injury research while emphasizing solvent control, timing, and orthogonal validation.
WZ4003: NUAK1/2 Inhibitor Workflow
2026-08-17
WZ4003 is a practical NUAK1/2 inhibitor for connecting target engagement with measurable changes in MYPT1 phosphorylation, cell-cycle progression, migration, invasion, and tau pathology. This workflow guide shows how to build better-controlled cell and brain-slice experiments while separating pathway-specific effects from general toxicity.
Necrostatin-1 for RIP1 Kinase Assays
2026-08-17
Build more interpretable necroptosis experiments with Necrostatin-1, a selective RIP1 kinase inhibitor for pathway-focused cell and tissue-injury studies. This guide also shows how to use it alongside, rather than confuse it with, ferroptosis workflows inspired by obesity-associated adipose stem cell research.
S1P/S1PR3 Signaling After Intracerebral Hemorrhage
2026-08-16
The reference study identifies S1PR3 as a regulator of neuronal apoptosis after acute intracerebral hemorrhage and connects this response to TNF-α, PI3K/AKT signaling, and caspase-3 activation. Its combination of mouse and HT22-cell experiments supports S1PR3 inhibition as a mechanistic strategy for studying secondary brain injury, while also highlighting the context-dependent effects of S1P signaling.
Gamithromycin: From Serum Signal to Strategy
2026-08-15
Gamithromycin, also known as ML-1709460, offers a powerful translational case study in how matrix effects, pulmonary distribution, and AUC24h/MIC can reshape antimicrobial decision-making. This evidence-led article connects ribosomal mechanism with serum-aware experimental design, veterinary respiratory applications, and practical development strategy.
Fluconazole for Candida Biofilm Research
2026-08-15
Fluconazole (SKU B2094) supports mechanistic studies of ergosterol disruption, Candida biofilm tolerance, and antifungal drug resistance. This guide connects stock preparation and susceptibility testing with the PP2A–autophagy findings reported in a recent Candida albicans study.
LL-37, KE-18, and KR-12 in Biofilm Control
2026-08-14
The reference study shows that truncating the human host-defense peptide LL-37 can preserve or improve selected antimicrobial activity, but biocidal potency does not predict antibiofilm performance. By comparing MIC, crystal violet, XTT, and bacterial surface-binding assays, the authors identify KE-18 as a promising biofilm-prevention peptide while demonstrating that prevention and inhibition are distinct phenotypes.
PMSF for Preserving Native Protein Complexes
2026-08-14
Phenylmethanesulfonyl fluoride (PMSF) is more than a routine extraction additive: it is a strategic tool for preserving proteome and complex integrity before biochemical measurement. This guide connects PMSF selectivity with recombinant eIF3 purification, Western blot reliability, and assay interpretation.
Netarsudil (AR-13324) in Reliable Cell Assays
2026-08-13
This scenario-driven guide explains how Netarsudil (AR-13324), SKU B7807, can improve the interpretation and handling of cell viability, proliferation, and cytotoxicity experiments. It connects ROCK biology, formulation compatibility, assay optimization, and siRNA-codelivery evidence to practical laboratory decisions.
Aclacinomycin A and the Logic of Nucleolar Stress
2026-08-13
Aclacinomycin A, or Aclarubicin, can serve as more than a cytotoxicity reagent: it is a strategic probe for connecting dual topoisomerase inhibition with persistent ribosomal DNA damage, PML-nucleolar responses, and apoptosis. This perspective translates recent genome-stability findings into practical assay and translational research guidance.
Merbromin Workflows for Fluorescence and Inhibition
2026-08-12
Merbromin is a versatile Mercury dibromofluorescein disodium salt for fluorescence-based binding analysis, pharmaceutical quantitation, and enzyme inhibition workflows. Its combination of static fluorescence quenching, visible absorbance, and resonance Rayleigh scattering enables low-solvent assays with orthogonal readouts.
461 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page